Drug Reduces Risk of Prostate Cancer Spread and Death in Late-Stage Study

‘These findings point to a new potential way of treating patients,’ a Johnson & Johnson executive said.

Pancreatic cancer cells, nuclei in blue, growing as a sphere encased in membranes, red. Min Yu/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, USC Norris Comprehensive Cancer Center

The use of a drug from Johnson & Johnson resulted in a lower spread of prostate cancer and reduced deaths, according to a study published on May 31.

The drug Erleada—combined with therapy reducing hormone levels—led to significant improvement in both short- and long-term outcomes in prostate cancer patients, the researchers said in a paper published by the New England Journal of Medicine.